Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.42 |
| ▸ | POLB | P06746 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 3/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | MLYCD | O95822 | 1/20 | 0.41 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Furfuryl Alcohol SCHEMBL1436757 | 0.87 | ALDH1A1 (0.47) | ALDH1A1KMT2APOLBMEN1MAPT | |
| Furfuryl Alcohol SCHEMBL37326 | 0.87 | — | — | |
| Furfuryl Alcohol SCHEMBL28270671 | 0.85 | — | — | |
| Furfuryl Alcohol SCHEMBL30524190 | 0.84 | — | — | |
| Furfuryl Alcohol SCHEMBL11661258 | 0.84 | ALDH1A1 (0.45) | ALDH1A1KMT2APOLBMEN1MAPT | |
| Furfuryl Alcohol SCHEMBL16415764 | 0.84 | — | — | |
| Furfuryl Alcohol SCHEMBL7904845 | 0.84 | — | — | |
| Furfuryl Alcohol SCHEMBL11661252 | 0.84 | — | — | |
| Furfuryl Alcohol SCHEMBL29092545 | 0.84 | — | — | |
| Furfuryl Alcohol SCHEMBL6417594 | 0.84 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1781816-A4 | COMPOSITIONS AND METHODS FOR RELEASING NUCLEIC ACIDS FROM SOLID PHASE BINDING MATERIALS | NEXGEN DIAGNOSTICS LLC (US) | 2008-03-05 | — | — | EP | claimed |
| EP-1781816-A1 | COMPOSITIONS AND METHODS FOR RELEASING NUCLEIC ACIDS FROM SOLID PHASE BINDING MATERIALS | LUMIGEN, INC. (US) | 2007-05-09 | — | — | EP | claimed |
| WO-2006019568-A1 | COMPOSITIONS AND METHODS FOR RELEASING NUCLEIC ACIDS FROM SOLID PHASE BINDING MATERIALS | LUMIGEN, INC. (US) | 2006-02-23 | — | — | WO | claimed |
| US-20050106589-A1 | Compositions and methods for releasing nucleic acids from solid phase binding materials | NEXGEN DIAGNOSTICS LLC | 2005-05-19 | — | — | US | claimed |
| EP-1789578-A4 | CLEAVABLE SOLID PHASES FOR ISOLATING NUCLEIC ACIDS | NEXGEN DIAGNOSTICS LLC (US) | 2008-02-27 | — | — | EP | disclosed |
| EP-1781808-A4 | METHODS OF USING CLEAVABLE SOLID PHASES FOR ISOLATING NUCLEIC ACIDS | LUMIGEN INC (US) | 2007-08-29 | — | — | EP | disclosed |
| EP-1789578-A2 | CLEAVABLE SOLID PHASES FOR ISOLATING NUCLEIC ACIDS | LUMIGEN, INC. (US) | 2007-05-30 | — | — | EP | disclosed |
| EP-1781808-A1 | METHODS OF USING CLEAVABLE SOLID PHASES FOR ISOLATING NUCLEIC ACIDS | LUMIGEN, INC. (US) | 2007-05-09 | — | — | EP | disclosed |
| WO-2006019388-A2 | CLEAVABLE SOLID PHASES FOR ISOLATING NUCLEIC ACIDS | LUMIGEN, INC. (US) | 2006-02-23 | — | — | WO | disclosed |
| WO-2006019387-A1 | METHODS OF USING CLEAVABLE SOLID PHASES FOR ISOLATING NUCLEIC ACIDS | LUMIGEN, INC. (US) | 2006-02-23 | — | — | WO | disclosed |
| US-20050106577-A1 | Comprises matrix of silica, glass, insoluble synthetic polymers, and insoluble polysaccharides as supports; peroxidases; proteases; glycosidases | NEXGEN DIAGNOSTICS LLC | 2005-05-19 | — | — | US | disclosed |
| US-20050106576-A1 | Methods of using cleavable solid phases for isolating nucleic acids | NEXGEN DIAGNOSTICS LLC | 2005-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050106589-A1 | Compositions and methods for releasing nucleic acids from solid phase binding materials | NSUN2, DNA2, DDX21 | ALDH1A1 4789/4885KMT2A 2790/4885POLB 31/4885 |
| US-20050106576-A1 | Methods of using cleavable solid phases for isolating nucleic acids | CPSF6, CPSF1, RNGTT | ALDH1A1 4641/4885KMT2A 1701/4885POLB 88/4885 |
| US-20050106577-A1 | Comprises matrix of silica, glass, insoluble synthetic polymers, and insoluble polysaccharides as supports; peroxidases; proteases; glycosidases | RNGTT, DNASE1, ENGASE | ALDH1A1 3358/4885KMT2A 2742/4885POLB 64/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.